Transcode Therapeutics Stock

Transcode Therapeutics EBITDA per Share

The EBITDA per Share of Transcode Therapeutics (RNAZ) as of Sep 4, 2026 is -1,233.13 USD. In the previous year, EBITDA per Share was -97,092.50 USD — a change of -98.73% (higher).

EBITDA per Share

-1,233.13USD

YoY

-98.73%

Last updated:

EBITDA per Share of Transcode Therapeutics is 2026 -1,233.13 USD. EBITDA per Share of Transcode Therapeutics was 2025 -97,092.50 USD. It decreases by -98.73% higher compared to the previous year.

The Transcode Therapeutics EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2023
-97,092.50 USD
Jan 1, 2024
-1,233.13 USD
The Transcode Therapeutics EBITDA per Share history
YEAREBITDA per ShareYoY
-1,233.13USD-98.73%
-97,092.50USD—
Access this data via the Eulerpool API
Get Free API Key

Transcode Therapeutics Stock analysis

What does Transcode Therapeutics do? Transcode Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transcode Therapeutics stock

EBITDA per Share of Transcode Therapeutics is -1,233.13 USD in 2026.

EBITDA per Share of Transcode Therapeutics changed from -97,092.50 USD to -1,233.13 USD, representing a -98.73% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Transcode Therapeutics since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API
Get Free API Key

Income Statement — Transcode Therapeutics

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Transcode Therapeutics